Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992–2003

Detalles Bibliográficos
Autores principales: Clarke, N.W., Ali, A., Ingleby, F.C., Hoyle, A., Amos, C.L., Attard, G., Brawley, C.D., Calvert, J., Chowdhury, S., Cook, A., Cross, W., Dearnaley, D.P., Douis, H., Gilbert, D., Gillessen, S., Jones, R.J., Langley, R.E., MacNair, A., Malik, Z., Mason, M.D., Matheson, D., Millman, R., Parker, C.C., Ritchie, A.W.S., Rush, H., Russell, J.M., Brown, J., Beesley, S., Birtle, A., Capaldi, L., Gale, J., Gibbs, S., Lydon, A., Nikapota, A., Omlin, A., O’Sullivan, J.M., Parikh, O., Protheroe, A., Rudman, S., Srihari, N.N., Simms, M., Tanguay, J.S., Tolan, S., Wagstaff, J., Wallace, J., Wylie, J., Zarkar, A., Sydes, M.R., Parmar, M.K.B., James, N.D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Corrigendum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929236/
https://www.ncbi.nlm.nih.gov/pubmed/32067690
http://dx.doi.org/10.1016/j.annonc.2020.01.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929236/
https://www.ncbi.nlm.nih.gov/pubmed/32067690
http://dx.doi.org/10.1016/j.annonc.2020.01.002

Ejemplares similares